E.g., 12/06/2021
E.g., 12/06/2021
PreviousNext

bioMérieux announces the CE marking of the new generation semi-quantitative VIDAS® SARS-COV-2 IgG II serology test.  

bioMérieux, a world leader in the field of in vitro diagnostics, today announces CE marking of the new generation of IgG serology test with VIDAS® SARS-COV-2 IgG II to semi-quantitatively detect antibodies in people who have been exposed to the SARS-CoV-2 that causes the COVID-19 disease.

07 May, 2021

In 2021, on top of the importance of detecting COVID-19 virus, the emergence of variant strains and expansion of vaccination have generated new public health challenges. In particular, obtaining quantitative serological information by measuring antibody levels might provide important insights to...

bioMérieux announces CE-marking of the new MALDI-TOF mass spectrometry identification system: VITEK® MS PRIME

bioMérieux, a world leader in the field of in vitro diagnostics, has announced the CE-marking of VITEK® MS PRIME, the next generation of the VITEK® MS MALDI-TOF1 mass spectrometry system for routine microbial identification in minutes.

30 April, 2021

Rapid microorganism identification is a pivotal step in the microbiology workflow. Over the past decade, MALDI-TOF mass spectrometry has transformed this process, providing critical information rapidly to clinicians in order to prescribe more effective antimicrobial therapy.

Including...

bioMérieux – First-Quarter 2021 Business Review

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31, 2021.

27 April, 2021

  • First-quarter organic growth of 16.5% at constant exchange rates and scope of consolidation : €845 million in sales, up 9.9% as reported.
  • Molecular biology up 19% over the quarter, with a slowdown in BIOFIRE® respiratory panels’ demand...

bioMérieux announces the CE marking of 3 dengue immunoassays on VIDAS®

bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE marking of its innovative and fully-automated assays to diagnose dengue infection: VIDAS® DENGUE NS1 Ag VIDAS® Anti-DENGUE IgM VIDAS® Anti-DENGUE IgG

07 April, 2021

Dengue is a viral disease transmitted to humans by certain types of mosquitoes. With 100 to 400 million people affected each year, it is the most common arthropod-borne viral infection worldwide. The global incidence of this infection has grown over 8 fold during the last 20 years, with the...

bioMérieux announces the CE marking of TB IGRA® test on VIDAS®  

Today marks World Tuberculosis (TB) Day and bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE marking of its innovative and fully-automated test VIDAS® TB IGRA (Interferon-Gamma Release Assay) to diagnose latent TB infection.

24 March, 2021

Tuberculosis continues to be a major global health problem. With 10 million new active cases and 1.4 million related deaths worldwide in 20191, TB remains an important cause of mortality from a single infectious disease. 

It is estimated that a fourth of the global...

BIOFIRE® Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 obtains De Novo FDA Authorization

Marcy l’Étoile (France) – bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in molecular syndromic infectious disease testing, has received U.S. Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE® RP2.1 Panel. 

18 March, 2021

This panel allows for the detection of 22 viral and bacterial pathogens responsible for respiratory infections, including SARS-CoV-2 (the cause of COVID-19 disease). The panel is the first SARS-CoV-2 diagnostic test of any kind that has been granted De Novo status by U.S. FDA, having gone...

The Biotech Digital Campus joins forces with biotechnology schools and training organizations to develop the talents of tomorrow

09 March, 2021

An unprecedented alliance serving the French bioproduction sector

"Recipient of a Future...

bioMérieux – 2020 Financial Results

24 February, 2021

  • €3,118 million in full-year 2020 sales, up 19.7 % like-for-like
  • Robust sales performance in the fourth quarter, with organic growth of 20.5 % led by sales of molecular biology reagents
  • Contributive operating...

bioMérieux announces the CE marking of NEPHROCHECK® test on VIDAS®

Marcy l’Etoile, France – February 3rd , 2021 – bioMérieux, a world leader in the field of in vitro diagnostics, today announced the CE marking of the innovative NEPHROCHECK® assay to detect kidney stress in patients at risk of acute kidney injury (AKI).

03 February, 2021

AKI is a common complication, affecting between 7 and 18% of all hospitalized patients1 and up to 50% of critically ill patients2. The condition is associated with a 10-fold increase in hospital mortality and a higher rate of chronic kidney disease among post-op patients...

bioMérieux announces the CE marking of its molecular biology ARGENE® test for the simultaneous detection of SARS-CoV-2, influenza viruses A and B, and RSV and hMPV viruses

Marcy l’Etoile, France – December 16, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, has announced the expansion of its ARGENE® range for the real-time PCR (RT-PCR) detection of SARS-CoV-2: the SARS-COV-2 RESPI R-GENE® test has received CE marking and is now commercially available.  

16 December, 2020

 
This high-throughput test,...

PreviousNext